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CASE REPORT
Sibutramine (Reductil
®)-Induced Cutaneous 
Leukocytoclastic Vasculitis: A Case Report
You Jin Ha, M.D., You Jin Han, M.D., You Won Choi, M.D., Ki Bum Myung, M.D., 
Hae Young Choi, M.D.
Department of Dermatology, School of Medicine, Ewha Womans University, Seoul, Korea
A 24-year old woman presented with hemorrhagic vesicles 
on her legs. She had taken sibutramine (Reductil
Ⓡ, Abbott 
Labs., Seoul, South Korea) for 3 months and developed skin 
lesions the week before. A skin biopsy showed leukocyto-
clastic vasculitis with conspicuous eosinophilic infiltration 
of the tissue. These lesions showed improvement after 
discontinuation of sibutramine. However, 3 months later the 
skin lesions recurred on other sites on the lower extremities 
when the patient was rechallenged with the same drug for 2 
weeks. Herein, we report the first case of necrotizing 
vasculitis induced by sibutramine. (Ann Dermatol 23(4) 544
∼547, 2011)
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INTRODUCTION
Sibutramine (Reductil
Ⓡ) is a selective monoamine reupta-
ke inhibitor
1. It is an orally administered, centrally acting, 
weight-management agent devoid of amphetamine-like 
abuse potential. Its amine metabolites are pharmacologi-
cally active and are thought to induce the natural pro-
cesses leading to enhanced satiety and thermogenesis by 
inhibiting serotonin and noradrenaline reuptake
2. Several 
clinical studies assessing the effectiveness and safety of 
sibutramine have shown that the drug is a safe and 
well-tolerated agent
1. Common side effects include dry 
mouth, constipation, nausea, and headache
1. The drug has 
been associated with increases in blood pressure and 
pulse rate
2. Cutaneous side effects such as urticaria, 
petechiae, mild skin eruption, and allergic hypersensitivity 
reaction have been rarely reported
2. Furthermore, a case 
report is available on an unusual adverse reaction of 
erythema multiform-like bullous drug eruption caused by 
sibutramine
3. 
Drug-induced vasculitis represents approximately 10% of 
acute cutaneous vasculitis cases
4 and is difficult to 
diagnose. Diagnosis and assessment of an underlying 
cause of a drug includes an analysis of features such as 
timing of drug exposure, onset, course of reaction, and 
nature of a recurrent eruption on rechallenge
5. 
Herein, we first report an interesting case of a patient with 
recurrent episodes of necrotizing vasculitis induced by 
sibutramine.
CASE REPORT
A 24-year old woman presented with hemorrhagic vesi-
cles on her legs. The skin lesions had appeared the week 
before. She had been taking 10 mg sibutramine once daily 
for 3 months, which had been prescribed at an adequate 
dose and appropriate manner. She had tolerant of the drug 
before the development of skin lesions. She was a student, 
and had no relevant medical history or any viral infection 
history. She had no travel or trauma history.
On physical examination, the patient had two overlying 
hemorrhagic vesicles on purple red patches on the right 
thigh and left calf (Fig. 1). She did not have any mucosal Sibutramine (Reductil
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Fig. 1. (A) Overlying hemorrhagic 
vesicles on a wheal-like patch of 
the right thigh. (B) A hemorrhagic 
vesicle on the left calf.
Fig. 2. Epidermal detachment with dense infiltrate in the upper
dermis and patchy cellular infiltration around the dermal blood 
vessels (H&E, ×40).
lesions. She was otherwise healthy, and had no history of 
fever, abdominal pain, or joint pain.
Kidney and liver function tests were within the normal 
range. C3 level was normal, and antinuclear and antineu-
trophil antibodies were absent. A urinalysis with micro-
scopy showed microscopic hematuria. Kidney ultrasono-
graphy revealed a small urinary stone but otherwise 
normal function.
A skin biopsy from the purpuric vesicular patch revealed 
perivascular cellular infiltration (Fig. 2). Dense perivas-
cular lymphohistiocytic infiltration with fibrinoid deposi-
tion in the vascular wall, red blood cell extravasation, 
nuclear dust, and endothelial swelling were observed 
revealing leukocytoclastic vasculitis (Fig. 3A). Conspicu-
ous eosinophils were evident in the dermis (Fig. 3B). The 
lesions showed obvious improvement after discontinuing 
the sibutramine followed by the administration of 10 mg 
prednisolone daily for 2 weeks.
Three months later, she visited our clinic again with a 
recurrence of similar skin lesions on other sites of the 
lower extremities (Fig. 4). A history revealed that she had 
taken sibutramine 2 weeks before lesion recurrence. 
Again, the patient was told to discontinue the sibutramine, 
and she improved substantially within 4 days.
DISCUSSION
Vasculitis is a diverse group of segmental inflammatory 
disorders and blood vessel necroses. Leukocytoclastic 
vasculitis involves mainly small vessels in the skin and 
generally manifests as palpable purpura on the lower 
extremities
6. Other features include hemorrhagic bullae, 
ulcers, nodules, and occasional digital necrosis
6. In our 
case, hemorrhagic vesicles and palpable purpura were 
found.
Diverse histological findings are noticeable, based on the 
inflammation period, Red blood cell extravasation, nu-
clear dust, and endothelial swelling are suggestive find-
ings of vasculitis
4. At least two histological components 
must occur to diagnose vasculitis: a perivascular inflam-
matory cell infiltrate and evidence of vascular injury
4. 
Necrosis of the vessel wall with deposition of fibrinoid 
material is a pathognomonic finding of vasculitis
4. This 
patient had all vasculitis findings such as red blood cell 
extravasation, nuclear dust, endothelial cell swelling, 
perivascular cellular infiltration, and fibrinoid deposition.
When cutaneous vasculitis is demonstrated histologically, 
every effort should be made to define the causative agent. 
If visceral diseases such as renal, pulmonary, or intestinal 
diseases are associated, an antineutrophil antibody study 
should be conducted to rule out Wegener’s granu-
lomatosis, microscopic polyangitis, and Churg Strauss 
syndrome. If antinuclear antibody or rheumatoid factors 
are present and dry eye or arthritis develops, then 
connective tissue disease vasculitis should be considered. 
If urticarial lesions are found clinically, urticarial vasculitis 
should be diagnosed. If a high fever or other infection 
signs are present, then infection-related vasculitis or septic YJ Ha, et al
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Fig. 3. (A) Fibrinoid deposition in the vascular wall, perivascular lymphoid cellular infiltration, red blood cell (RBC) extravasation, 
and nuclear dust (H&E, ×400). (B) Conspicuous eosinophils, RBC extravasation, and endothelial cell swelling (H&E, ×400).
Fig. 4. A purpuric vesicular patch recurred on the right calf after
rechallenging the patient with sibutramine 3 months later.
vasculitis should be considered. Paraneoplastic vasculitis 
should be suspected if hematological abnormalities or 
abnormal masses are found on imaging studies, and the 
lesions do not improve with corticosteroids. If there is a 
history of drug intake, drug-induced vasculitis should be 
considered. 
Drug-induced vasculitis represents approximately 10% of 
acute cutaneous vasculitis cases
5. It can be difficult to 
diagnose and is often a diagnosis of exclusion
6. Other 
causes for cutaneous vasculitis, such as infection or 
autoimmune disease, must be excluded. Diagnosis and 
assessment of an underlying drug etiology consists of 
analyzing features such as timing of drug exposure, 
reaction onset, course of reaction with drug withdrawal or 
continuation, timing and nature of a recurrent eruption on 
rechallenge, and previous reports of similar reactions to 
the same medication
6. A skin biopsy should be considered 
for patients with potentially severe reactions, such as those 
with erythroderma, blistering, skin tenderness, purpura, or 
pustulation
6. Tissue eosinophilia may be an indicator of 
drug etiology in patients with cutaneous small vessel 
vasculitis
7. The therapeutic approach can be divided into 
antigen removal and treatment of the cutaneous 
vasculitis
8. Withdrawal of the precipitating medication is 
mandatory. Treatment for cutaneous vasculitis consists of 
preventing the deposition of immune complexes, and 
suppressing the inflammatory response
8. H1 antihista-
mines are used to alleviate lesional symptoms and to 
reduce tissue deposition of circulating immune com-
plexes. Nonsteroidal anti-inflammatory agents are com-
bined with an H1 antihistamine, and colchicine or hydro-
xychloroquine sulfate can be added to or substituted for 
these agents
8. If there is still no therapeutic response, 
systemic glucocorticoids or other immunosuppressants 
(azathioprine, methotrexate, cyclophosphamide, cyclos-
porine) should be considered
8. 
In our case, as similar skin lesions recurred after a 
rechallenge with sibutramine, the offending drug was 
sibutramine. Moreover, conspicuous eosinophilic infil-
tration of the tissue on histological examination suggested 
a drug etiology. 
Sibutramine has been increasingly used since obesity has 
become a social issue. It is a selective monoamine 
reuptake inhibitor, primarily of serotonin and norad-
renaline
1. It is a centrally acting weight-management drug, 
devoid of amphetamine-like abuse potential
2. Overall, 
selective serotonin reuptake inhibitors are safe, and 
adverse effects are mainly associated with gastrointestinal 
tract symptoms such as nausea, vomiting, or diarrhea. Sibutramine (Reductil
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Previous studies of vasculitic reactions associated with 
selective serotonin reuptake inhibitor therapy have been 
reported. Case reports of urticarial vasculitis secondary to 
fluoxetine
9 and paroxetine
10 have also been documented. 
Leukocytoclastic vasculitis after administering citalopram 
for 2 months has been reported
11. A patient who 
developed cutaneous vasculitis while taking proxetine for 
4 months has also been reported
12.
Serotonin plays a role in blood clotting, evokes smooth 
muscle contraction, and narrows blood vessels.
Therefore, manipulating serotonin levels may result in 
abnormal cutaneous or visceral manifestation
13. The 
ability of serotonin to induce and augment platelet 
aggregation following vascular inflammation may explain 
the vasculitic reaction. Further studies are needed to 
identify the exact mechanism of the induction of vasculitis 
by selective serotonin reuptake inhibitors.
No reports are available on drug-induced vasculitis 
associated with sibutramine. Thus, this is the first reported 
case of cutaneous leukocytoclastic vasculitis caused by 
sibutramine.
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